ArticleFrontiers in immunology2026
Integrative pan-cancer analysis of dipeptidyl peptidase 4 with clinical and
Article in Frontiers in immunology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Metabolic convergence of diabetes and prostate cancer: from dysglycemia to tumor microenvironment reprogramming.Mammalian genome : official journal of the International Mammalian Genome Society · 2026Review
- IntegratingFrontiers in immunology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Dipeptidyl peptidase 4 (DPP4) plays diverse physiological roles, but its pan-cancer significance and immunomodulatory functions remain poorly characterized. Methods: We performed an integrative pan-cancer analysis of DPP4, incorporating transcriptomic, genomic, and immunogenomic approaches. Differential expression, ceRNA networks, protein interactions, immune infiltration, drug sensitivity, molecular docking, and molecular dynamics were systematically evaluated. Single-cell sequencing analysis, virtual knockout analysis and TIDE analysis were conducted to validate the role of DPP4 in prostate cancer. Further clinical validation was conducted in a prostate cancer cohort (n=97) using immunohistochemistry, Kaplan-Meier survival analysis, and clinicopathological correlation studies were also conducted. DPP4 expression was assessed by qPCR in 22Rv1 and C4-2 cells treated with dasatinib or midostaurin at IC Results: DPP4 exhibited tumor-specific dysregulation across multiple cancer types. Its expression correlated significantly with patient prognosis, tumor stage, genomic alterations, immune cell composition, and therapeutic response. In prostate cancer, DPP4 was markedly downregulated ( Conclusion: Our study establishes DPP4 as a multifaceted pan-cancer biomarker with prognostic significance and immunotherapeutic implications, particularly in prostate cancer.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.